Jon Kallay, Sr. Technology & Market Development Manager, Microbial Solutions

COVID-19 has defined the start of a new phase for biopharmaceuticals and their related aspects in manufacturing, quality control, and regulation. The  issues of acceleration, product supply, manufacturing capacity, innovative technologies, high-throughput manufacturing, and rapid analytical testing are not new, but the pandemic has increased the urgency for the industry to make changes and accelerate pharmaceutical innovation. See how Celsis rapid microbial detection instruments can be used for several applications within the new era of biomanufacturing.

Download the Poster Watch the Presentation Summary